A novel isoflavone, ME-344, targets the cytoskeleton in acute myeloid leukemia

The isoflavone ME-344 is a potent anti-cancer agent with preclinical and clinical efficacy in solid tumors. Yet, the mechanism of action of ME-344 has not been fully defined and the preclinical efficacy in leukemia has not been established. Therefore, we investigated the anti-leukemic properties and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Jeyaraju, Danny V., Hurren, Rose, Wang, Xiaoming, MacLean, Neil, Gronda, Marcela, Shamas-Din, Aisha, Minden, Mark D., Giaever, Guri, Schimmer, Aaron D.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2016
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5226547/
https://ncbi.nlm.nih.gov/pubmed/27391350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10446
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak